Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGMB-447 in Healthy Participants and Idiopathic Pulmonary Fibrosis
NCT06181370Phase 1Completed
- Sponsor
- Agomab Therapeutics
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing AGMB-447 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events at 8 weeks, Number of participants with abnormal clinical laboratory values at 8 weeks and 4 more. Started Dec 2023; status: completed.
02
Drugs
AGMB-447
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06181370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181370.